Aqualax

Quick links to important sections

Aqualax

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aqualax

Quick Facts

Property Description
Active ingredient Macrogol (Polyethylene Glycol)
Form Oral powder for solution
Pharmacological class Osmotic laxative
General purpose To ease the passage of stool
Origin Synthetic polyglycol

Aqualax: What Type of Medicine is It?

Aqualax is a medication formulated with the active substance Macrogol (Polyethylene Glycol), which is scientifically classified as an osmotic laxative or osmotic agent. This classification reflects the drug's action as a physical, non-systemic intervention for the gastrointestinal tract. Macrogol itself is a biologically inert, synthetic polyglycol, characterized by its high molecular weight. As an osmotic agent, Aqualax differs from stimulant laxatives, which directly provoke muscle contractions, making it suitable for providing gentle relief from the discomfort associated with infrequent or difficult bowel movements, a common use scenario.


Composition and Pharmaceutical Preparation

The core component is typically Macrogol 3350 or Macrogol 4000, a polymer that remains non-absorbable by the body, limiting its effect to the bowel. Aqualax is most often supplied as an oral powder for solution, intended to be dissolved in a liquid before ingestion via the oral route. Many preparations are formulated as a fixed-dose combination medication, including balanced electrolytes such as Sodium Chloride and Potassium Chloride to help maintain electrolyte balance during the osmotic action.


Core Principle: How Aqualax Provides Relief

Aqualax provides relief through a specific, gentle osmotic mechanism: the Macrogol polymer acts as a solute that draws and retains water inside the bowel lumen. This physiological action increases the water content and volume of the stool mass. The overall purpose of this effect is to facilitate the natural, smooth passage of stool, making the evacuation process easier and more comfortable by achieving a softer, bulkier material.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Aqualax?

Possible Side Effects and Safety Information

This section details the officially documented adverse reactions and safety characteristics of Aqualax (Macrogol), as recorded in government regulatory documents.

Official Adverse Reactions and Frequency

Adverse reactions are classified based on the frequency reported in clinical data and post-marketing surveillance. The effects are primarily categorized under Gastrointestinal Disorders, reflecting the medicine's non-absorbable nature.

Frequency Classification Documented Side Effects
Common (up to 1 in 10 people) Abdominal pain, bloating (distension), diarrhea, nausea.
Uncommon (up to 1 in 100 people) Vomiting, urgent need to go to the toilet.
Not Known (cannot be estimated) Allergic reactions (including anaphylactic shock), seizure, oesophageal rupture (Boerhaave syndrome).

Serious Adverse Reactions and System-Organ Classes

The regulatory label documents rare, clinically significant reactions, particularly affecting the Immune System and Nervous System.

  • Serious Adverse Reactions: Officially listed serious events include anaphylactic shock and seizure. Cases of oesophageal rupture have also been reported, predominantly in elderly patients following intense vomiting.
  • Time-Related Pattern: Diarrhea, a common reaction, typically resolves when treatment is stopped or the dose is reduced, suggesting a transient and dose-dependent effect.

Safety Restrictions and Population Notes

The use of Aqualax is strictly restricted in certain health contexts to prevent risk, as defined in prescribing information.

  • Contraindications: Aqualax is contraindicated (should not be used) in individuals with known intestinal perforation or obstruction (or suspicion thereof), severe forms of inflammatory bowel disease (e.g., toxic megacolon), or a known allergy to polyethylene glycol.
  • Population Notes: Caution is officially advised for elderly patients and those with renal impairment, particularly due to the potential for electrolyte disturbances when using Macrogol-electrolyte formulations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Aqualax (Macrogol) overdose is primarily defined by the consequences of its osmotic action. Overdose, which occurs when doses exceed the maximum recommended amount, is typically characterized by diarrhea and excessive stool frequency. These gastrointestinal manifestations can lead to serious dehydration and subsequent electrolyte disturbances, which are the main risks documented by regulatory authorities.

When to Seek Immediate Medical Attention

Immediate medical attention is mandated when symptoms escalate beyond simple gastrointestinal discomfort. Seek immediate medical attention and contact a Poison Control Center if an overdose is suspected. Urgent medical evaluation is required if the victim exhibits severe signs of fluid and electrolyte shift, such as confusion, seizure, profound thirst, or signs of collapse. Emergency services must be called if the individual has collapsed, had a seizure, or cannot be awakened.

Supportive Management

There is no specific antidote for Macrogol overdose. Treatment is symptomatic and supportive, focusing on the essential correction of fluid and electrolyte abnormalities. Regulatory documents note that elderly patients and those with existing renal or hepatic impairment are particularly vulnerable to severe electrolyte imbalances and require careful monitoring of serum electrolytes and pH.

Therapeutic Uses of Aqualax

What Aqualax Treats: Main Uses and Benefits

Aqualax is commonly used across domains where short-term symptomatic assistance is needed to address pronounced discomfort and manage symptoms that interfere with daily functioning during acute episodes. It is generally applied in contexts where additional symptomatic support is needed, primarily focusing on conditions involving systemic imbalance and inflammatory or irritative states. Specific symptomatic areas include distressing gastrointestinal manifestations and acute physical discomfort related to temporary strain. Medications in this class may be part of symptomatic management to help with symptoms related to functional stress.

Aqualax is relevant when symptom clusters create noticeable interference with daily comfort or escalate temporarily. It assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods. This approach is considered relevant when supportive symptom management is appropriate: It supports patients during episodes of heightened discomfort by easing distress. It is commonly used when symptoms become temporarily overwhelming, offering symptomatic relief that may help patients cope more steadily with difficult episodes.

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus overview of Stool Softeners

Eligibility and Restrictions for Use

Aqualax (Macrogol) eligibility is defined by regulatory bodies across specific patient populations and pre-existing medical conditions. The use of this medicine is restricted to ensure patient safety, particularly given its osmotic action within the gastrointestinal tract.


Eligibility Scope

Category Official Regulatory Status
Contraindicated Populations Must not be used by patients with: Bowel perforation or risk of perforation; Intestinal obstruction (ileus); Toxic megacolon; severe Inflammatory Bowel Disease (e.g., Crohn's Disease, Ulcerative Colitis); or known Hypersensitivity to Macrogol.
Age-Group Eligibility Approved for most adults and adolescents (12 years and older). Use in children under 12 requires medical prescription; specific pediatric formulations are approved for chronic use starting as young as 6 months in some regions.
Conditional Use (Caution) Caution is required for older adults and patients with existing renal impairment or cardiac insufficiency. These populations may require monitoring due to the risk of fluid and electrolyte imbalances associated with the drug’s osmotic action.
Pregnancy and Lactation Permitted. Official guidelines state that use is compatible during both pregnancy and breastfeeding due to the negligible systemic absorption of the Macrogol component.

Connection to the overall eligibility profile

Regulatory documents establish strict absolute contraindications for patients whose gastrointestinal integrity is compromised, such as those with obstruction or perforation. For other groups, including children, the elderly, and those with certain chronic conditions, eligibility is either permitted or requires caution, ensuring its non-systemic nature is safely managed across diverse patient profiles.

What should I know about interactions with other medicines?

Aqualax (Macrogol/Polyethylene Glycol) has an officially documented interaction profile focused primarily on its physical effects within the gastrointestinal tract and its impact on fluid balance. No clinically significant drug-drug interactions involving Cytochrome P450 (CYP) enzymes have been demonstrated, consistent with its non-systemic mode of action.

Pharmacokinetic and Timing Restrictions

Due to the accelerated gastrointestinal transit caused by Aqualax, the systemic exposure (absorption) of all other oral medications may be reduced. Regulatory documents therefore require that oral medications be separated by at least one hour when starting a full bowel cleansing solution dose. For routine co-administration, some official health authorities advise a separation of two hours.

Pharmacodynamic and Substance Interactions

The pharmacodynamic interaction pattern centers on fluid and electrolyte homeostasis. Co-administration with medicinal products that also affect electrolyte levels, such as Diuretics, ACE-Inhibitors, ARBs, and NSAIDs, may increase the risk for fluid and electrolyte disturbances. In a high-dose regimen, Aqualax is formally restricted from being co-administered with other laxatives.

A specific physical substance interaction is documented with starch-based food thickeners, where Macrogol counteracts the thickening effect. Furthermore, patients taking medications that lower the seizure threshold, such as Tricyclic Antidepressants, are noted as a specific population at increased risk of seizure due to the combination of their medication and Macrogol-induced electrolyte changes.

Mechanism of Action

Physicochemical Modulation via Osmotic Retention

Aqualax (Macrogol) is a non-systemic agent that works through a purely physicochemical mechanism, relying on hydrogen bonding to sequester water molecules within the colonic lumen. This action creates an osmotic gradient that opposes the colon's physiological drive to reabsorb fluid, increasing the hydration and volume of the fecal mass.


Mechanical Activation of Colonic Propulsion

The resulting increase in fecal bulk leads to the mechanical distension of the colonic wall, which is the sole driver of the drug's effect on motility. This physical stretching activates the intrinsic distension reflex, physiologically stimulating peristaltic movement. The cascade results in the formation of a bulkier, softer stool mass, which accelerates propulsion through the lower gastrointestinal tract.


️ Constraint and Complementary Balance

The entire mechanism is constrained by the Macrogol polymer's necessary high molecular weight, which prevents its absorption and ensures its localized action. Furthermore, the inclusion of electrolytes in the formulation serves a complementary function by maintaining the solution's iso-osmotic balance, thereby mitigating osmotic-driven fluid and ionic shifts.

Dosage and Administration Information

Official Administration Guidelines

Aqualax, a Macrogol 3350 preparation, is designed exclusively for administration via the oral route after reconstitution as a solution. The medicine is not intended for injection or any other route. The proper use protocol is defined by specific quantitative instructions regarding dosage, preparation, and duration.


Standard Dosing and Preparation

The typical adult dosage involves taking one 17 gram (g) dose of the powder once daily. In various regional contexts, the standard regimen for general use involves 1 to 3 sachets daily, often taken in divided doses, with each sachet commonly containing 13.125 g of Macrogol 3350. For specific acute conditions, such as faecal impaction, a high-dose regimen of up to 8 sachets daily is specified, which must be consumed within a six-hour period.

Proper preparation is mandatory for use. The powder must be fully dissolved in a liquid prior to ingestion. A 17 g dose requires dissolution in 4 to 8 ounces of fluid, while a 13.125 g sachet typically requires 125 mL of water. The solution can be consumed with or without food.


Duration and Special Use Constraints

The initial period of use is generally restricted to a short term to provide symptomatic relief. Use generally should not exceed seven days to two weeks for initial treatment. For patients requiring a long-term plan, such as those with chronic conditions, the dose may be adjusted down for maintenance under medical supervision. Specific administration guidance applies to certain populations. No dosage change is necessary for older adults or patients with renal impairment. A critical procedural constraint is that the Macrogol powder must not be combined with starch-based thickeners used for swallowing difficulties, as this can counteract the thickener's efficacy.

Recent Clinical Evidence

Research evidence / Overview of studies for Aqualax

Evidence for Use in Functional/Chronic Constipation

The research landscape includes studies that have examined Macrogol for conditions marked by functional limitations related to the frequency and ease of stool passage. Studies exploring short-term symptom changes include numerous Randomized Controlled Trials (RCTs) and systematic reviews. The primary functional outcomes that researchers monitored related to physical discomfort, including the weekly number of bowel movements and the stool consistency.

Findings describe patterns observed in the studies related to measurements of changes in weekly bowel movements. Research has explored various Macrogol formulations; studies monitored how electrolyte measurements evolved during the study period in formulations that included electrolytes.

Evidence for Use in Acute Fecal Impaction

Macrogol was evaluated in research exploring acute or disruptive episodes, specifically focusing on the short-term management of retained stool mass. These studies were primarily short-term RCTs, often focused on pediatric populations. Studies monitored physiological strain and other functional outcomes reflecting the aim of relieving retained stool.

Research describes patterns observed in the short time interval of the study regarding the evacuation of retained stool. Comparative evidence is lacking for certain subgroups in adult populations, and there is limited information for long-term outcomes related to the rate of re-impaction.

Long-Term Studies and Maintenance

Long-term effects are not fully established for the continuous, uninterrupted use of Macrogol. Research has monitored continuous use for up to six months, but certainty remains low regarding the durability of responses over multiple years. Studies provide insight into short-term changes, but follow-up durations were limited in the majority of controlled research.

Research in Special Populations

Specific RCTs have explored use in pediatric patients (children and adolescents). However, data for certain groups remain insufficient. Research for patients with complex comorbid conditions or very older adults often uses smaller observational study designs. Results apply only to the populations studied in existing trials, and comparative evidence for these special populations is often lacking.

Key Studies & References

  1. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
  2. Fecal Impaction - StatPearls (Review of treatment options, including PEG for proximal impaction)

Frequently Asked Questions (FAQ)

Common questions about Aqualax (FAQ)

Q: Is Aqualax the same as a regular laxative?

Aqualax is classified as an osmotic laxative. This class of medicine works by drawing water into the bowel to soften and increase the volume of the stool. This mechanism is different from that of other laxative classes, such as stimulants, which have a different method of action.

Q: What's the difference between Aqualax and other prescription options for this condition?

Aqualax (Macrogol) is a non-systemic osmotic agent, meaning that its action is localized to the bowel and the substance is not absorbed into the body. Other prescription options may belong to different pharmacological classes, which work via different mechanisms.

Q: Why do some people say Aqualax didn't work for them?

Regulatory information indicates that Macrogol may take one to two days to start working, and it may take longer to achieve the full beneficial effect. Official guidance suggests that if a person does not see improvement after three days, they may need to seek advice from their healthcare provider.

Q: What is the general expectation for improvement when using Aqualax?

Research and official documents describe the intended improvement in terms of increased stool consistency and the weekly number of bowel movements. The drug's stated purpose is to promote the easier passage of stool by increasing its water content and bulk.

Q: Does Aqualax treat the underlying condition or just the symptoms?

The general purpose of Aqualax is to ease the passage of stool, which means it provides symptomatic relief. It works by creating a softer, bulkier stool material to facilitate evacuation, rather than addressing the underlying causes of the condition.

Q: Is Aqualax a brand name, and are there generic versions?

Aqualax is a specific product name. The active substance in the medicine is called Macrogol (also known as Polyethylene Glycol). This substance is the generic name, and many products containing Macrogol are available.

Q: Is it true that Aqualax is only approved for short-term use?

Official labeling generally restricts the initial period of use to a short term, such as seven to fourteen days. However, official documents also note that for patients who require ongoing support, the medicine may be used for a maintenance regimen under medical supervision.

Q: Can a person take other over-the-counter remedies while on Aqualax?

Because Aqualax accelerates transit through the gut, the systemic absorption of all other oral medications, including certain over-the-counter remedies, may be reduced. Health authorities advise a separation of at least one to two hours between taking Aqualax and other oral products.

Q: Is there an official list of all drugs that interact with Aqualax?

Regulatory documents describe the interaction profile, which primarily focuses on medicines that affect electrolyte levels (e.g., Diuretics and NSAIDs). Due to the drug's non-systemic nature, no clinically significant drug-drug interactions involving CYP-enzymes have been demonstrated. The main risk involves reduced absorption of other oral medications.

Q: How quickly should I expect Aqualax to start working?

Official guidance states that Macrogol can typically take one to two days to start producing an effect. Official guidance suggests that if a person does not see improvement after three days, they may need to seek advice from their healthcare provider.

Q: What happens if I forget to take Aqualax for a day?

Regulatory guidance advises to skip the missed dose and take the next dose at the usual time. Regulatory guidance states that a person should not take two doses at the same time to compensate for a forgotten one.

Q: Is it true that Aqualax can interact with blood thinners?

Aqualax may reduce the absorption of all other oral medications, including oral blood thinners, due to accelerated transit through the gastrointestinal tract. Regulatory guidance advises separating the intake of oral medications by at least one to two hours.

Q: Does Aqualax interact with birth control pills?

Official regulatory guidance specifically notes that Macrogol preparations do not affect the efficacy of combined oral contraceptive pills, progestogen-only pills, or emergency contraception.

Q: What happens to the body when someone stops taking Aqualax?

Aqualax is a non-systemic agent that is not absorbed into the body. Once the use of Macrogol is stopped, its physical action of retaining water in the bowel ceases. Official documents and research do not typically describe formal withdrawal or dependency effects upon discontinuation.

Q: Is it possible to develop a dependency on Aqualax?

Macrogol is an osmotic laxative that works through a physical process of water retention and does not stimulate the nerves or muscles of the bowel. Dependency is generally associated with other types of laxatives that rely on stimulating the nerves or muscles of the bowel.

Q: Why is Aqualax taken at a specific time of day?

Official guidance states that it does not matter what time of day Macrogol is taken. However, taking it at the same time each day may help a person to establish a consistent routine.

Q: Can Aqualax affect my ability to drive or operate machinery?

Regulatory documents specifically state that Macrogol preparations generally have no known influence on a person's ability to drive and use heavy machinery.

Q: How long does the effect of Aqualax last after a dose?

Macrogol is not absorbed and its effect is directly related to the movement of the substance through the bowel. Its osmotic action is transient, meaning it ceases once the medicine has passed through the system during the accelerated gastrointestinal transit period.

Q: Is Aqualax described as being safe for people with liver disease?

Due to the medicine’s non-systemic and non-metabolized action, liver disease is not typically listed in regulatory documents as an absolute contraindication.

Q: Can I take Aqualax with my vitamins and supplements?

Yes, but the systemic absorption of vitamins and supplements taken orally may be reduced due to the accelerated transit time caused by Aqualax. It is advised to separate the intake of Aqualax and other oral products by at least one to two hours.

Q: Can Aqualax be crushed or split if a person has trouble swallowing?

Aqualax is supplied as a powder for an oral solution, not a tablet. The powder must be fully dissolved in the specified amount of liquid prior to ingestion. The powder is not intended to be consumed directly or mixed straight into solid food.

Q: Does taking Aqualax impact blood sugar levels?

Official safety profiles for Macrogol do not list an impact on blood sugar levels as a common or serious adverse reaction. Some formulations may be described as suitable for use by people who manage blood sugar.

Q: What are the non-drug ways of supporting the treatment Aqualax provides?

Official health guidance often recommends non-drug supporting measures. These may include the gradual introduction of increased dietary fiber and ensuring adequate fluid intake to help support bowel function.

Q: Are there specific symptoms that mean a person should stop taking Aqualax?

Regulatory documents list several serious adverse reactions that require immediate medical attention. These include signs of an allergic reaction (e.g., swelling of the face, difficulty breathing) or signs of severe fluid or electrolyte imbalance (e.g., seizure, severe weakness).

Q: What type of specialist typically prescribes Aqualax?

Macrogol is commonly initiated by a general healthcare professional, such as a GP, nurse, or pharmacist. It may be prescribed by a specialist, like a gastroenterologist, if the condition requires more complex management.

Q: Is it common for side effects from Aqualax to go away after a few weeks?

Diarrhea, a common side effect, typically resolves when the treatment is stopped or the dose is reduced, suggesting a transient effect. Official information does not explicitly state that all side effects resolve after a fixed number of weeks of continuous use.

Q: Is Aqualax described as safe for people with high blood pressure?

Caution is advised for patients taking medication for high blood pressure due to the potential for the drug's osmotic action to cause changes in fluid and electrolyte balance. This possibility is why caution is advised, and it may require attention from a healthcare provider.

Q: What is the typical time frame described in research for seeing the full effect of Aqualax?

Research indicates that initial effects are typically seen within one to two days. However, achieving the full beneficial effect in terms of sustained, improved bowel movement frequency and consistency may take a longer period to establish.

Q: Is it important to keep track of certain symptoms while using Aqualax?

Regulatory cautions advise vigilance for signs of potential fluid or electrolyte disturbances, especially in older adults and those with kidney issues. Tracking symptoms such as increasing tiredness, swelling, or changes in mood may be important.

Q: Are headaches a common or uncommon side effect of Aqualax?

Headaches are described in some official patient information as a possible symptom associated with a change in the body's fluid or electrolyte levels. They may be noted as a less frequent or serious adverse reaction.

Q: Is Aqualax available over the counter, or is it prescription only?

In many regions, Macrogol preparations are available for general purchase or as pharmacy-only (P) medicines. Specific higher doses for acute use or pediatric formulations may require a medical prescription (Rx).

How should Aqualax be stored and disposed of?

How to Store and Dispose of Aqualax

Storage and disposal instructions for Aqualax must follow official labeling to maintain product stability and safety.

Storage Conditions

Preparation Form Required Conditions
Dry Powder Store at Controlled Room Temperature (20 C to 25 C). Keep in the original container and sealed tightly closed and protected from excess heat, moisture, and direct light.
Reconstituted Solution Must be refrigerated (2 C to 8 C), not frozen, and must be discarded after 48 hours.

Handling and Disposal

The medicine must be stored out of the reach of children. Do not keep outdated or unneeded medicine. For proper disposal of unused Aqualax, patients are instructed to consult a healthcare professional for specific guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aqualax found in:

A-Z Index: